» Articles » PMID: 32085654

Role of VEGFs/VEGFR-1 Signaling and Its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2020 Feb 23
PMID 32085654
Citations 84
Authors
Affiliations
Soon will be listed here.
Abstract

The vascular endothelial growth factor (VEGF) family members, VEGF-A, placenta growth factor (PlGF), and to a lesser extent VEGF-B, play an essential role in tumor-associated angiogenesis, tissue infiltration, and metastasis formation. Although VEGF-A can activate both VEGFR-1 and VEGFR-2 membrane receptors, PlGF and VEGF-B exclusively interact with VEGFR-1. Differently from VEGFR-2, which is involved both in physiological and pathological angiogenesis, in the adult VEGFR-1 is required only for pathological angiogenesis. Besides this role in tumor endothelium, ligand-mediated stimulation of VEGFR-1 expressed in tumor cells may directly induce cell chemotaxis and extracellular matrix invasion. Furthermore, VEGFR-1 activation in myeloid progenitors and tumor-associated macrophages favors cancer immune escape through the release of immunosuppressive cytokines. These properties have prompted a number of preclinical and clinical studies to analyze VEGFR-1 involvement in the metastatic process. The aim of the present review is to highlight the contribution of VEGFs/VEGFR-1 signaling in the progression of different tumor types and to provide an overview of the therapeutic approaches targeting VEGFR-1 currently under investigation.

Citing Articles

Untangling the Role of MYC in Sarcomas and Its Potential as a Promising Therapeutic Target.

Sias F, Zoroddu S, Migheli R, Bagella L Int J Mol Sci. 2025; 26(5).

PMID: 40076599 PMC: 11900228. DOI: 10.3390/ijms26051973.


Vascular endothelial growth factor A: friend or foe in the pathogenesis of HIV and SARS-CoV-2 infections?.

van der Mescht M, Steel H, Anderson R, Rossouw T Front Cell Infect Microbiol. 2025; 14:1458195.

PMID: 40008234 PMC: 11850333. DOI: 10.3389/fcimb.2024.1458195.


Comparative safety profile of tyrosine kinase inhibitors in NSCLC: a network meta-analysis of hypertension and thrombotic risks.

Tan M, Pu C, Wang Z, Jin C Front Pharmacol. 2025; 16:1491990.

PMID: 39944617 PMC: 11813866. DOI: 10.3389/fphar.2025.1491990.


Probing structural requirements for thiazole-based mimetics of sunitinib as potent VEGFR-2 inhibitors.

Abd Elhameed A, Ali A, Ghabbour H, Bayomi S, El-Gohary N RSC Med Chem. 2025; .

PMID: 39850549 PMC: 11753467. DOI: 10.1039/d4md00754a.


Leveraging the synergy between anti-angiogenic therapy and immune checkpoint inhibitors to treat digestive system cancers.

Xu Q, Shao D Front Immunol. 2024; 15:1487610.

PMID: 39691707 PMC: 11649667. DOI: 10.3389/fimmu.2024.1487610.


References
1.
Stacker S, Stenvers K, Caesar C, Vitali A, Domagala T, Nice E . Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J Biol Chem. 1999; 274(45):32127-36. DOI: 10.1074/jbc.274.45.32127. View

2.
Sarabipour S, Ballmer-Hofer K, Hristova K . VEGFR-2 conformational switch in response to ligand binding. Elife. 2016; 5:e13876. PMC: 4829425. DOI: 10.7554/eLife.13876. View

3.
List A, Glinsmann-Gibson B, Stadheim C, Meuillet E, Bellamy W, Powis G . Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells. Exp Hematol. 2004; 32(6):526-35. DOI: 10.1016/j.exphem.2004.03.005. View

4.
Yang P, Hsieh M, Huang Y, Hsieh C, Chiang T, Lee J . Genetic variants of EGF and VEGF predict prognosis of patients with advanced esophageal squamous cell carcinoma. PLoS One. 2014; 9(6):e100326. PMC: 4063891. DOI: 10.1371/journal.pone.0100326. View

5.
Huang T, Fu L . The immune landscape of esophageal cancer. Cancer Commun (Lond). 2019; 39(1):79. PMC: 6878621. DOI: 10.1186/s40880-019-0427-z. View